BrainStorm Cell Therapeutics Inc. has presented promising results on the Phase 2a clinical trial of its product NurOwn® for amyotrophic lateral sclerosis (ALS) at the 67th American Academy of Neurology Annual Meeting, which took place this year in Washington D.C from April 18-25. The presented poster was entitled…
In a new study entitled “Phase I Trial of Repeated Intrathecal Autologous Bone Marrow-derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis,” researchers performed a safety study with stem cells based therapy to treat Amyotrophic Lateral Sclerosis patients and concluded it as a safe and promising therapy. The…
AB Science SA, a pharmaceutical company focused on research, development and marketing of protein kinase inhibitors (PKIs), has announced that it is hosting a web conference including key opinion leaders and experts covering its experimental therapy masitinib and its utility to treat amyotrophic lateral sclerosis (ALS). The web conference call will be held from 5:35…
A research team from Pitié–Salpêtrière Hospital in Paris found major structural alterations of the neuromuscular junctions (NMJs) in early stage Amyotrophic Lateral Sclerosis (ALS) patients. The study entitled “Endplate denervation correlates with Nogo-A muscle expression in amyotrophic lateral sclerosis patients” was published April 2015 in…
A researcher from Baltimore is going to receive $130,000 to support her research on the most frequent subtype of familial amyotrophic lateral sclerosis (ALS); the funds come from the Clinical Research Training Fellowship in ALS, co-sponsored by the ALS Association and American Brain Foundation. The award was presented during the largest meeting of…
A new study recently published in the journal Acta Neuropathologica Communications revealed that the absence of the FUS/TLS protein, which has been linked to neurological diseases, causes symptoms distinct from the ones found in amyotrophic lateral sclerosis (ALS) patients. The study is entitled “FUS/TLS…
Biopharmaceutical company MediciNova, Inc. recently announced in a press release that the initial results of an ongoing clinical trial for the drug MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) were presented by the study’s principal investigator Dr. Benjamin Rix Brooks at the 2015 American Academy of Neurology (AAN)…
In a highly unusual move, last Friday the U.S. Food and Drug Administration (FDA) issued a statement calling on pharmaceutical firm Genervon to release all data pertaining to a recent small study involving the company’s ALS drug candidate GM604. In its statement, the FDA affirms that it…
Cyberdyne Inc. recently applied for a marketing authorization of HAL® for Medical Use (Lower Limb Type) for orphan neural-muscular diseases like amyotrophic lateral sclerosis and muscular dystrophy as a new medical device under Japan’s Pharmaceutical and Medical Device Law. In Japan, it is required that new medical devices under the…
The ALS Association together with the Harvard Stem Cell Institute, and the Neurological Clinical Research Institute at Massachusetts General Hospital recently announced in a press release a collaboration with GlaxoSmithKline (GSK) in a clinical trial to assess a potential therapy with an anti-epileptic drug in…
